Milestone Leqembi approval is “a mixed bag,” analysts say, given drug label’s risk warnings and infusion-center bottlenecks.
You are here: Home / Top Stories / The Ratings Game: Biogen’s big Alzheimer’s drug win fails to boost the stock as analysts see slow Leqembi rollout